Half-Year Liquidity Contract Statement for LYSOGENE
05 Luglio 2021 - 6:00PM
Business Wire
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform
Company targeting central nervous system (CNS) diseases, today
presents the half-year report on the liquidity contract signed by
Lysogene with Kepler Cheuvreux.
Under the liquidity contract entered into between LYSOGENE and
Kepler Cheuvreux, the following resources appeared on the liquidity
account on June 30th 2021:
- 43,579 shares - € 132,063.33 - Number of
executions on buy side on semester: 369 - Number of executions on
sell side on semester: 399 - Traded volume on buy side on semester:
125,130 shares for € 358,888.31 - Traded volume on sell side on
semester: 131,937 shares for € 400,135.60
As a reminder:
- the following resources appeared on the last half year
statement on 31 December 2020 on the liquidity account:
- 50,386 shares - € 91,098.95 - Number of
executions on buy side on semester: 303 - Number of executions on
sell side on semester: 278 - Traded volume on buy side on semester:
96,720 shares for € 217,955.50 - Traded volume on sell side on
semester: 90,522 shares for € 215,280.25
- the following resources appeared on the liquidity account when
the activity started:
- 34,030 shares - € 78,185.94
The liquidity agreement complies with AMF Decision n° 2018-01
dated 2nd July 2018, introducing liquidity agreements on equity
securities as permitted market practice.
Buy Side
Sell Side
Number of executions
Number of shares
Traded volume (€)
Number of executions
Number of shares
Traded volume (€)
Total
369
125,130
358,888.31
399
131,937
400,135.60
04/01/2021
-
-
-
15
2500
7 025.00
05/01/2021
7
3 399
9 143.31
1
500
1 425.00
06/01/2021
1
500
1 325.00
2
500
1 370.00
07/01/2021
-
-
-
1
500
1 370.00
08/01/2021
6
1 500
3 900.00
3
500
1 350.00
11/01/2021
-
-
-
15
9500
29 450.00
12/01/2021
6
4 500
12 420.00
-
-
-
13/01/2021
7
4 000
10 640.00
-
-
-
14/01/2021
1
500
1 325.00
-
-
-
15/01/2021
2
1 000
2 580.00
-
-
-
18/01/2021
6
1 500
3 750.00
1
500
1 300.00
19/01/2021
1
500
1 250.00
1
500
1 275.00
20/01/2021
4
1 000
2 480.00
-
-
-
21/01/2021
-
-
-
6
1500
3 825.00
22/01/2021
6
1 500
3 750.00
-
-
-
25/01/2021
16
5 000
11 700.00
1
150
375.00
26/01/2021
2
500
1 150.00
1
500
1 175.00
27/01/2021
-
-
-
4
2000
4 980.00
28/01/2021
4
2 000
4 620.00
-
-
-
29/01/2021
3
500
1 150.00
-
-
-
01/02/2021
-
-
-
15
7000
17 500.00
02/02/2021
1
500
1 250.00
1
500
1 300.00
03/02/2021
-
-
-
16
5000
13 400.00
04/02/2021
-
-
-
14
5000
14 550.00
05/02/2021
4
1 500
4 200.00
6
1500
4 425.00
08/02/2021
-
-
-
14
5000
15 400.00
09/02/2021
9
2 700
8 343.00
-
-
-
10/02/2021
7
2 000
5 960.00
2
1000
3 140.00
11/02/2021
3
1 000
2 900.00
18
9069
29 111.49
12/02/2021
2
1 000
3 680.00
33
7500
27 900.00
15/02/2021
2
500
1 925.00
20
7000
29 540.00
16/02/2021
21
6 536
24 117.84
-
-
-
17/02/2021
14
6 221
21 586.87
1
500
1 850.00
18/02/2021
16
6 804
21 772.80
-
-
-
19/02/2021
3
1 500
4 635.00
9
3000
9 840.00
22/02/2021
2
1 000
3 230.00
8
2000
6 760.00
Buy Side
Sell Side
Number of executions
Number ofshares Tradedvolume (€)
Number of executions
Number of shares
Tradedvolume (€)
23/02/2021
23
4 500
14 985.00
4
2000
7 160.00
24/02/2021
1
500
1 625.00
3
1000
3 280.00
25/02/2021
-
-
-
12
4000
13 640.00
26/02/2021
9
3 500
11 410.00
7
1000
3 380.00
01/03/2021
-
-
-
6
1157
3 899.09
02/03/2021
2
500
1 645.00
-
-
-
03/03/2021
6
2 000
6 380.00
-
-
-
04/03/2021
11
3 500
10 815.00
-
-
-
05/03/2021
5
1 500
4 500.00
-
-
-
08/03/2021
2
500
1 475.00
2
500
1 510.00
09/03/2021
1
500
1 475.00
8
2006
6 278.78
10/03/2021
1
500
1 550.00
3
494
1 556.10
11/03/2021
-
-
-
1
500
1 575.00
12/03/2021
-
-
-
3
500
1 575.00
15/03/2021
2
1 000
3 060.00
-
-
-
16/03/2021
1
500
1 500.00
-
-
-
17/03/2021
-
-
-
3
1000
3 030.00
18/03/2021
3
500
1 495.00
-
-
-
19/03/2021
10
2 000
5 760.00
-
-
-
22/03/2021
3
1 000
2 880.00
3
1000
2 930.00
23/03/2021
1
500
1 425.00
-
-
-
24/03/2021
2
1 000
2 780.00
-
-
-
25/03/2021
4
1 000
2 730.00
1
500
1 420.00
26/03/2021
-
-
-
2
500
1 375.00
29/03/2021
-
-
-
4
1000
2 830.00
30/03/2021
1
500
1 400.00
4
500
1 450.00
31/03/2021
-
-
-
3
1000
2 880.00
01/04/2021
1
500
1 395.00
1
500
1 425.00
06/04/2021
2
500
1 400.00
-
-
-
08/04/2021
1
1
2.79
2
501
1 402.80
09/04/2021
2
500
1 400.00
1
500
1 425.00
12/04/2021
1
500
1 400.00
-
-
-
13/04/2021
-
-
-
3
1500
4 350.00
14/04/2021
2
1 000
2 880.00
-
-
-
15/04/2021
2
201
570.84
-
-
-
Buy Side
Sell Side
Number of executions
Number of shares
Traded volume (€)
Number ofexecutions Number ofshares Tradedvolume
(€)
16/04/2021
-
-
-
1
7
20.30
19/04/2021
-
-
-
1
493
1 429.70
20/04/2021
3
500
1 400.00
-
-
-
21/04/2021
1
500
1 375.00
-
-
-
22/04/2021
3
1 000
2 930.00
9
3000
8 940.00
23/04/2021
4
1 500
4 260.00
-
-
-
26/04/2021
1
500
1 400.00
-
-
-
27/04/2021
2
500
1 400.00
3
500
1 425.00
28/04/2021
-
-
-
4
1000
2 830.00
29/04/2021
3
500
1 400.00
-
-
-
30/04/2021
4
500
1 375.00
-
-
-
03/05/2021
-
-
-
2
500
1 400.00
06/05/2021
1
500
1 375.00
-
-
-
07/05/2021
-
-
-
2
500
1 375.00
11/05/2021
9
2 000
5 260.00
1
500
1 325.00
12/05/2021
4
1 500
3 825.00
-
-
-
13/05/2021
6
2 000
4 960.00
-
-
-
14/05/2021
-
-
-
14
4000
10 760.00
17/05/2021
2
500
1 300.00
1
500
1 350.00
18/05/2021
1
1
2.63
3
226
598.90
19/05/2021
1
1
2.63
1
1
2.63
20/05/2021
4
500
1 275.00
-
-
-
24/05/2021
4
1 000
2 580.00
3
775
2 030.50
25/05/2021
7
2 000
4 960.00
1
500
1 300.00
26/05/2021
7
1 500
3 630.00
2
272
680.00
27/05/2021
3
1 500
3 525.00
-
-
-
02/06/2021
1
500
1 175.00
-
-
-
03/06/2021
-
-
-
2
1000
2 430.00
04/06/2021
4
500
1 200.00
-
-
-
07/06/2021
-
-
-
5
728
1 798.16
08/06/2021
-
-
-
7
2500
6 575.00
09/06/2021
8
3 869
9 788.57
-
-
-
10/06/2021
-
-
-
13
5000
13 300.00
11/06/2021
-
-
-
21
9000
27 000.00
14/06/2021
3
1 500
4 275.00
-
-
-
15/06/2021
3
2 000
5 520.00
4
1000
2 930.00
16/06/2021
10
4 896
12 729.60
1
500
1 400.00
Buy Side
Sell Side
Number of executions
Number ofshares Tradedvolume (€)
Number of executions
Number of shares
Traded volume (€)
17/06/2021
5
2 000
4 980.00
-
-
-
18/06/2021
2
1 000
2 430.00
2
500
1 250.00
21/06/2021
1
500
1 175.00
-
-
-
22/06/2021
-
-
-
4
1000
2 430.00
23/06/2021
1
1
2.43
4
1501
3 752.50
24/06/2021
-
-
-
2
1000
2 480.00
25/06/2021
2
500
1 200.00
-
-
-
28/06/2021
2
500
1 175.00
1
57
139.65
30/06/2021
2
1 000
2 280.00
1
500
1 175.00
About Lysogene
Lysogene is a gene therapy Company focused on the treatment of
orphan diseases of the central nervous system (CNS). The Company
has built a unique capability to enable a delivery of gene
therapies to the CNS to treat lysosomal diseases and other genetic
disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in
partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive
clinical trial in GM1 gangliosidosis is ongoing. In accordance with
the agreements signed between Lysogene and Sarepta Therapeutics,
Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial
rights to LYS-SAF302 in the United States and markets outside
Europe; and Lysogene will maintain commercial exclusivity of
LYS-SAF302 in Europe. Lysogene is also collaborating with an
academic partner to define the strategy of development for the
treatment of Fragile X syndrome, a genetic disease related to
autism. www.lysogene.com.
Forward Looking Statement
This press release may contain certain forward-looking
statements, especially on the Company’s progress of its clinical
trials and cash runway. Although the Company believes its
expectations are based on reasonable assumptions, all statements
other than statements of historical fact included in this press
release about future events are subject to (i) change without
notice, (ii) factors beyond the Company’s control, (iii) clinical
trial results, (iv) increased manufacturing costs and (v) potential
claims on its products. These statements may include, without
limitation, any statements preceded by, followed by or including
words such as “target,” “believe,” “expect,” “aim,” “intend,”
“may,” “anticipate,” “estimate,” “plan,” “objective”, “project,”
“will,” “can have,” “likely,” “should,” “would,” “could” and other
words and terms of similar meaning or the negative thereof.
Forward-looking statements are subject to inherent risks and
uncertainties beyond the Company’s control that could cause the
Company’s actual results, performance or achievements to be
materially different from the expected results, performance or
achievements expressed or implied by such forward-looking
statements. A further list and description of these risks,
uncertainties and other risks can be found in the Company’s
regulatory filings with the French Autorité des Marchés Financiers,
including in the 2020 universal registration document, registered
with the French Markets Authorities on April 12, 2021, under number
D.21-0296, and future filings and reports by the Company.
Furthermore, these forward-looking statements are only as of the
date of this press release. Readers are cautioned not to place
undue reliance on these forward-looking statements. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future. If the Company updates one or more
forward-looking statements, no inference should be drawn that it
will or will not make additional updates with respect to those or
other forward-looking statements.
This press release has been prepared in both French and English.
In the event of any differences between the two texts, the French
language version shall supersede.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210705005277/en/
Stéphane Durant des Aulnois Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com + 33 1 41 43 03 99